Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zealand Pharma A/S (OP: ZLDPF )

121.03 +6.03 (+5.24%)
Streaming Delayed Price Updated: 2:42 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 490
Open 120.00
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 115.00
Today's Range 119.76 - 121.03
52wk Range 40.40 - 141.74
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns. 
Via Benzinga
International Small-Cap ETF Reaches 52-Week High, Leaving Investors Wondering What's Next
SCZ, an ETF tracking small-caps outside of NA, hits 52-wk high at $65.60. Strong performance of top holdings and bullish trends point to continued success. 
Via Benzinga
Topics ETFs

Performance

YTD
+131.19%
+131.19%
1 Month
+0.77%
+0.77%
3 Month
+2.07%
+2.07%
6 Month
+35.23%
+35.23%
1 Year
+182.78%
+182.78%

More News

Read More
Move Aside Ozempic, WeGovy: Denmark's New Drug Just Showed Positive Results For Weightloss
Via Benzinga
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
Via InvestorPlace
Topics ETFs
Obesity Drug Achieves ~15% Weight Loss - Zealand Pharma-Boehringer Ingelheim Partnered Drug May Compete With Novo Nordisk, Eli Lilly
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.